Pre-made Nurulimab biosimilar ( Whole mAb, anti-CTLA4 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-382
Anti-CTLA4 therapeutic antibody (Pre-made Nurulimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Nurulimab (also known as BCD 145) is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for the treatment of cancer
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CTLA4 therapeutic antibody (Pre-made Nurulimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None|
|99% SI Structure||5xj3:AB/5tru:HL/6jc2:HL|
|95-98% SI Structure||None|
|Conditions Discontinued||Malignant melanoma|